Search Clinical Trials
Thank you for your interest in research at UTMB! Taking part in research is one way to be part of tomorrow’s healthcare discoveries. UTMB is always looking for volunteers just like you so that our researchers can better understand how to prevent, diagnose, and treat diseases. Everyone is needed. Both healthy volunteers and people with health conditions can help us answer important questions that impact the health of our communities. Ready to start searching for a study to be involved with? • Enter a health condition or leave it blank if you are looking to join any study as a healthy volunteer • Enter your gender and age • Click “View Results” • Click on the study titles for information • Click on the “Contact/Details” tab to get information for contacting the study team
Sponsor Condition of Interest |
---|
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
BioNTech SE
SARS-CoV-2 Virus
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
The purpose of this clinical trial is to learn about the safety, extent of the side effects,
and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine)
in healthy children. The trial is divided into 5 individual studies or substudies based on... expand
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. - Substudy A design: Phase 1 includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial series, followed by a fourth dose of study vaccine. Phase 2/3 includes participants 6 months through less than 5 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive 1, 2, or 3 doses of study vaccine, depending on what group they are in. - Substudy B design: includes participants 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. - Substudy C design: Phase 1 includes participants 6 months through less than 5 years of age who have received 3 prior doses of BNT162b2 and will receive study vaccine as their fourth dose. - Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. - Substudy E design: includes participants 2 through less than 12 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive a single dose of study vaccine. Type: Interventional Start Date: Sep 2022 |
Correlates of CRCI and Gut Microbiome Dysbiosis; a Pilot Study
The University of Texas Medical Branch, Galveston
Cancer
The aim of this study is to characterize the microbiome and assess fatigue and cognition of
patients with cancer undergoing standard of care treatment.
expand
The aim of this study is to characterize the microbiome and assess fatigue and cognition of patients with cancer undergoing standard of care treatment. Type: Observational Start Date: Mar 2024 |
Effectiveness of Healthy Habits for Hospitalized Older Adults to Optimize Rehabilitation
Baylor College of Medicine
Insomnia
Pain
Osteoarthritis, Knee
Osteoarthritis, Hip
This study aims to evaluate behavioral interventions in conjunction with medical
rehabilitation to promote functional health in patients recovering from orthopedic surgery.
Half of the subjects in this study will be assigned to an intervention that meets with a
study therapist... expand
This study aims to evaluate behavioral interventions in conjunction with medical rehabilitation to promote functional health in patients recovering from orthopedic surgery. Half of the subjects in this study will be assigned to an intervention that meets with a study therapist to discuss implementing healthy habits. The other half of subjects will assigned to an intervention group that meets with a study therapists to discuss implementing healthy sleep habits. Both groups will undergo several physical and cognitive assessments. Type: Interventional Start Date: Apr 2021 |
The Effect of Clinic Visit Audio Recordings for Self-management in Older Adults
Dartmouth-Hitchcock Medical Center
Diabetes
The objective of this study is to conduct a multisite trial evaluating the impact of adding
an audio recording of clinic visits (AUDIO) to usual care in older adults with
multimorbidity, including diabetes, compared to After Visit Summary (AVS) alone (Usual Care;
UC).... expand
The objective of this study is to conduct a multisite trial evaluating the impact of adding an audio recording of clinic visits (AUDIO) to usual care in older adults with multimorbidity, including diabetes, compared to After Visit Summary (AVS) alone (Usual Care; UC). Type: Interventional Start Date: Sep 2023 |
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial...
Eagle Pharmaceuticals, Inc.
Pneumonia, Bacterial
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in
treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia
(SCABP) requiring critical care measures
expand
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures Type: Interventional Start Date: Jul 2023 |
LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational...
Boston Scientific Corporation
Heart Failure
The primary objective of this study is to collect sensor data from insertable cardiac monitor
systems.
expand
The primary objective of this study is to collect sensor data from insertable cardiac monitor systems. Type: Interventional Start Date: Mar 2021 |
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV...
Alliance for Clinical Trials in Oncology
Brain and Central Nervous System Tumors
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as temozolomide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. It is not yet known whether giving
radiation... expand
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma. Type: Interventional Start Date: Sep 2009 |
Understanding the Long-term Impact of COVID on Children and Families
NYU Langone Health
SARS-CoV-2 Infection
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of
individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at
varying stages before and after infection. Individuals with and without SARS-CoV-2 infection... expand
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and participants will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptoms will be reported by participants or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization. Type: Observational Start Date: Mar 2022 |
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and...
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or
without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating
patients with triple negative breast cancer that has spread to other places in the body
(metastatic).... expand
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer. Type: Interventional Start Date: Apr 2021 |
A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
The George Washington University Biostatistics Center
Short Cervical Length
This protocol outlines a randomized trial of 630 women evaluating the use of micronized
vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in
women carrying twins and with a cervical length of less than 30 millimeters.
expand
This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters. Type: Interventional Start Date: Nov 2015 |
Longitudinal Study of the Porphyrias
Icahn School of Medicine at Mount Sinai
Acute Porphyrias
Cutaneous Porphyrias
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation
of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and
mortality in people with these disorders.
expand
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders. Type: Observational Start Date: Nov 2010 |
CCT-102 vs. Expectant Management in Delayed Pregnancy Loss
Conceptra Biosciences, LLC
Early Pregnancy Loss, Delayed Pregnancy Loss
A Phase 3, multi-center clinical trial of a CCT-102 regimen compared to expectant management
to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss
(DPL).
expand
A Phase 3, multi-center clinical trial of a CCT-102 regimen compared to expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL). Type: Interventional Start Date: Dec 2023 |
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Duke University
Lactating Women on Select DOI
Breastfed Infants of Mothers on Select DOI
Over half of women in the US who are breastfeeding their infants take prescription drugs. You
are being asked to participate in this study because you are breastfeeding your infant and
are currently taking, as part of your medical care, at least one of the drugs we are
studying.... expand
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by breastfed infants. Type: Observational Start Date: Oct 2018 |
Treatment of ppROM With Erythromycin vs. Azithromycin Trial
The University of Texas Medical Branch, Galveston
Preterm Premature Rupture of Membranes (PPROM)
Preterm premature rupture of membranes (PPROM) complicates 4% of pregnancies annually. This
pregnancy complication is a major contributor to preterm births and results in neonatal
morbidity and mortality. The current standard of care for PPROM subjects between the
gestational... expand
Preterm premature rupture of membranes (PPROM) complicates 4% of pregnancies annually. This pregnancy complication is a major contributor to preterm births and results in neonatal morbidity and mortality. The current standard of care for PPROM subjects between the gestational age of 24 weeks and 0 days and 33 weeks and 6 days, is to administer ampicillin and erythromycin for a total of 7 days. Erythromycin can cause GI upset and some subjects do not tolerate this regimen over the course of 7 days. In addition, there is a national shortage of erythromycin, and published expert opinion proposed to use a second-generation macrolide (azithromycin) instead of erythromycin. Azithromycin can be taken once daily, is cheaper than erythromycin and has less GI upset adverse effects. The investigators' objective is to compare the effectiveness of the 2 regimens in prolonging pregnancy after PPROM. The investigators' working hypothesis is that there is no measurable difference in the primary outcome between the group randomized to the azithromycin regimen versus the group randomized to the erythromycin regimen. Type: Interventional Start Date: Feb 2017 |
Healthy Communities Through CHW Initiatives
The University of Texas Medical Branch, Galveston
Diabetes Mellitus, Type 2
Latino(a)s suffer from poor social determinants of health (SODH) conditions more than
non-minority populations, and being a minority is risk factor alone for diabetes. In the
proposed study, investigators will assist church members in becoming Community Health Workers
(CHWs),... expand
Latino(a)s suffer from poor social determinants of health (SODH) conditions more than non-minority populations, and being a minority is risk factor alone for diabetes. In the proposed study, investigators will assist church members in becoming Community Health Workers (CHWs), train them in diabetes, and use an online platform (Salesforce) to track the ability to address healthcare access and quality barriers. Type: Interventional Start Date: Aug 2023 |
Prospective Analysis to Detect Myometrial Cells in Peritoneal Washing in Patients Undergoing Minimally...
The University of Texas Medical Branch, Galveston
Hysterectomy
The Aim of the study is to determine endometrial/myometrial spillage during total
laparoscopic hysterectomy with manual morcellation.
expand
The Aim of the study is to determine endometrial/myometrial spillage during total laparoscopic hysterectomy with manual morcellation. Type: Observational Start Date: Aug 2023 |
Above-Knee-High Application of Lower Limb Compression and Its Impact on Clinical Outcome in Patients...
The University of Texas Medical Branch, Galveston
Heart Failure; With Decompensation
Lower Extremity Edema
Heart Failure,Congestive
Heart failure (HF) remains one of the most common causes of hospitalization with high
morbidity and mortality, and its worldwide prevalence is increasing. Despite notable progress
in outcomes for HF the rate of early rehospitalization for HF (re-HHF) remains high,
especially... expand
Heart failure (HF) remains one of the most common causes of hospitalization with high morbidity and mortality, and its worldwide prevalence is increasing. Despite notable progress in outcomes for HF the rate of early rehospitalization for HF (re-HHF) remains high, especially in the first 30 days. The rate of 30-day HF rehospitalization in the claims databases of the USA and in worldwide randomized clinical trials is 20-25% and 5-10% respectively. In patients with bilateral leg edema, the presence of CHF (congestive heart failure) as the factor causing or worsening local leg swelling should be evaluated. Application of local leg compression can be considered in stable CHF patients without decompensated heart function (NYHA Class I and II) for both CHF-related edema treatment and for treatment of concomitant diseases leading to leg swelling occurrence. Current literature does not have recommendations on the routine use of lower limb compression in leg swelling related to end stage heart disease and advanced, decompensated heart failure. Potential benefits of applying medical compression in more severe classes of CHF (NYHA Class III and IV) would need to be evaluated by further randomized clinical studies to determine which cohort of patients would benefit most from lower limb compression, as well as to choose the safest and most efficient compression protocol for these patients. The AIM of this study is to improve the clinical outcome of patients admitted with exacerbation of heart failure with associated volume overload. The primary objectives are: 1) diminish the duration of hospitalization of CHF patients; 2) decrease the incidence of rehospitalization from CHF exacerbation and 3) prevent local complications associated with prolonged lower extremity edema. The investigators hypothesize that the application of local compression to bilateral lower extremities, when added to guideline-based therapy for CHF exacerbation, will improve overall clinical outcome in patients at the University of Texas Medical Branch (UTMB). If our intervention is proven to be beneficial, it could lead to a significant reduction in nationwide hospitalization costs associated with heart failure. Type: Interventional Start Date: Apr 2022 |
Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery
The University of Texas Medical Branch, Galveston
Operative Time
Wound Heal
Despite the high numbers of cesareans being performed, scientific evidence behind which
surgical techniques are best remains uncertain. Our objective is to determine if subcuticular
absorbable staples improve operative time and wound cosmetics.
expand
Despite the high numbers of cesareans being performed, scientific evidence behind which surgical techniques are best remains uncertain. Our objective is to determine if subcuticular absorbable staples improve operative time and wound cosmetics. Type: Interventional Start Date: Nov 2021 |
Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor
The University of Texas Medical Branch, Galveston
Labor Long
The goal of this clinical trial is to compare oxytocin infusion rates for induction and
augmentation of labor in nulliparous women. The main question[s] it aims to answer are:
- Does a high dose oxytocin infusion protocol affect length of induction to delivery
interval?... expand
The goal of this clinical trial is to compare oxytocin infusion rates for induction and augmentation of labor in nulliparous women. The main question[s] it aims to answer are: - Does a high dose oxytocin infusion protocol affect length of induction to delivery interval? - Does a high dose oxytocin infusion protocol affect mode of delivery? - Does a high dose oxytocin infusion protocol affect maternal and neonatal outcomes? Participants will be randomized to either low- or high-dose oxytocin groups: - The low dose group will receive an infusion to start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. The maximum rate of infusion is 40 milli-units/min. - The high dose group will receive an infusion to start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Type: Interventional Start Date: Apr 2023 |
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction...
Eli Lilly and Company
Heart Failure
Heart Failure With Preserved Ejection Fraction
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults
with worsening heart failure with preserved ejection fraction
expand
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction Type: Interventional Start Date: Feb 2023 |
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants...
Janssen Research & Development, LLC
Urinary Bladder Neoplasms
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in
participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus
concurrent chemoradiotherapy.
expand
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy. Type: Interventional Start Date: Dec 2020 |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive...
Alliance for Clinical Trials in Oncology
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in
preventing breast cancer from coming back (relapsing) in patients with high risk, HER2
positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a
chemotherapy... expand
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Type: Interventional Start Date: Jan 2021 |
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Vertos Medical, Inc.
Lumbar Spinal Stenosis
This prospective longitudinal study will compare incidence rates of Medicare beneficiary
surgical and minimally invasive intervention post index procedure, as well as harms
associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a
control... expand
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by the sponsor. Type: Observational Start Date: Mar 2017 |
Point of Care Ultrasound in Obstetric Triage
The University of Texas Medical Branch, Galveston
Ultrasound
Fetal Monitoring
The research will find out if using portable ultrasound devices by nurses can make it quicker
to get babies from 24 to 32 weeks on the doppler monitor.
expand
The research will find out if using portable ultrasound devices by nurses can make it quicker to get babies from 24 to 32 weeks on the doppler monitor. Type: Interventional Start Date: Oct 2023 |
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Triple-Negative Breast Carcinoma
Unresectable Malignant Solid Neoplasm
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination
with binimetinib in treating patients with solid tumors that carry RAS alterations and that
have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery... expand
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN003694 is an oral medication with potential anticancer activity. It is an inhibitor of a family of proteins called bromodomain and extra-terminal (BET) which play important role during development and cellular growth. ZEN003694 may stop the growth of tumor cells that produce BET. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action proteins called MEK1 and MEK2, that signal cancer cells to multiply. It may help keep cancer cells from growing and spreading. There is pre-clinical evidence that using ZEN003694 and binimetinib together may shrink or stabilize cancers studied in this trial. There are two parts of this study; dose escalation and dose expansion. In the dose escalation part of this study, different people will get different doses of the study drugs ZEN003694 and binimetinib. In the dose expansion part of this study, the highest dose with manageable side effects will be given to additional people. This will help to understand the side effects that may happen with this drug combination. Type: Interventional Start Date: Aug 2022 |